Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) Director Daniel Swisher, Jr. sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $74.07, for a total transaction of $111,105.00. Following the completion of the sale, the director owned 1,100 shares of the company’s stock, valued at approximately $81,477. The trade was a 57.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Corcept Therapeutics Price Performance
CORT stock traded down $0.81 on Friday, hitting $72.90. 1,112,919 shares of the company were exchanged, compared to its average volume of 1,469,770. The stock has a market capitalization of $7.98 billion, a price-to-earnings ratio of 57.40 and a beta of 0.54. Corcept Therapeutics Incorporated has a twelve month low of $28.66 and a twelve month high of $126.38. The business’s fifty day moving average is $104.49 and its two-hundred day moving average is $76.30.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The biotechnology company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.17. Corcept Therapeutics had a net margin of 16.53% and a return on equity of 22.56%. The company had revenue of $340.47 million for the quarter, compared to analyst estimates of $339.12 million. During the same quarter last year, the business earned $0.16 EPS. Corcept Therapeutics’s revenue for the quarter was up 64.0% on a year-over-year basis. Equities research analysts expect that Corcept Therapeutics Incorporated will post 1.97 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Corcept Therapeutics in the second quarter worth about $1,080,964,000. Parallel Advisors LLC raised its stake in Corcept Therapeutics by 2.5% during the 1st quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock valued at $160,329,000 after acquiring an additional 96,763 shares in the last quarter. First Trust Advisors LP raised its stake in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after acquiring an additional 1,480,059 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Corcept Therapeutics during the 2nd quarter worth $49,185,000. Finally, Bank of America Corp DE acquired a new position in shares of Corcept Therapeutics during the second quarter valued at $28,569,000. 93.61% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the company. Weiss Ratings raised Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Piper Sandler reissued an “overweight” rating and set a $173.00 price target (up from $165.00) on shares of Corcept Therapeutics in a research report on Wednesday, November 4th. Wall Street Zen upgraded Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Truist Financial began coverage on Corcept Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price objective on the stock. Finally, Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective on the stock. in a research note on Monday, July 27th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $139.50.
View Our Latest Research Report on Corcept Therapeutics
About Corcept Therapeutics
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Read More
- Five stocks we like better than Corcept Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
